- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of May 21
The Center for Biosimilars® recaps the top 5 articles for the week of May 21, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 21.
Number 5: Both a disease activity score in a count of 28 joints and a score on a short-form mental health survey may be able to predict which patients with rheumatoid arthritis will experience a disease flare if they try to taper their anti—tumor necrosis factor therapy.
Number 4: The FDA has released a new series of educational videos on biosimilars and interchangeable products.
Number 3: At this week’s International Society for Pharmacoeconomics and Outcomes Research’s (or ISPOR’s) 23rd Annual International Meeting, researchers reported that, while biosimilars have a longer history in Europe than they have in the United States, challenges to uptake still linger.
Number 2: In a Monday workshop at the ISPOR meeting, Mike Blum, MD, MPH, of the FDA, addressed the role of postmarketing surveillance in the US biosimilars market.
Number 1: The European Commission has granted marketing authorization to Sandoz’s infliximab biosimilar, Zessly.
Finally, last week, our e-newsletter asked whether you think that the President’s drug pricing plan goes far enough to address Americans’ concerns over the high cost of healthcare.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Top 5 Most-Read Regulatory Articles of 2024
December 25th 2024In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
December 10th 2024The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
